<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01859819</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC-157</org_study_id>
    <secondary_id>L 10,753</secondary_id>
    <nct_id>NCT01859819</nct_id>
  </id_info>
  <brief_title>Treatment for Advanced B-Cell Lymphoma</brief_title>
  <acronym>REBOOT</acronym>
  <official_title>Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To safely reduce the burden of therapy in children, adolescents and young adults with mature
      B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT
      Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline
      (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy
      backbone (Immunochemotherapy).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if disease response rate will improve with this combination of therapy.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine if the addition of intrathecal ([IT] [Depocyt®]) and reduction of standard IT dosing and the reduction of anthracycline exposure (doxorubicin) (60%) within the ANHL01P1 FAB/LMB B4 + Rituximab chemoimmunotherapy backbone in children, adolescents and young adults with good risk CD20+ mature B-NHL (Stage I and II unresected and Stage III/IV with LDH &lt; 2 UNL) will result in similar response rates compared to historical controls (Subgroup I).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if the combination of IT Depocyte®, Rituximab and FAB Chemotherapy is safe.</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the safety and efficacy of reduction of IT therapy and substitution with L-ARA-C (Depocyte®) within ANHL01P1 FAB/LMB Group C1 plus rituximab chemotherapy backbone in children, adolescents and young adults with advanced risk de-novo mature B-NHL (Group C BM±CNS) (Subgroup II) as measured by reported serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <condition>Burkitt's Lymphoma</condition>
  <condition>High Grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH &lt;2 X ULN.
REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-ALL (&gt; 25% Bone marrow blasts) without CNS involvement.
REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>De-novo Mature CD 20 + B-NHL with CNS involvement:
Any L3 blasts in CSF
Cranial nerve palsy (if not explained by extracranial tumor)
Clinical spinal cord compression
Isolated intracerebral mass
Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <other_name>RITUXAN®, IDEC-C2B8) NSC #687451, IND #10385</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IT Cytarabine</intervention_name>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C, CNS negative</arm_group_label>
    <arm_group_label>Group C, CNS Positive</arm_group_label>
    <other_name>DEPOCYT® (Cytarabine Liposome Injection)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed mature B-lineage (CD20 positive) Leukemia/Lymphoma

          -  1. Diffuse Large Cell Lymphoma (NOT primary mediastinal B-cell lymphoma) -2. Burkitt's
             Lymphoma

          -  3. High Grade B-cell Lymphoma---Burkitt's like.

        B-Cell Anaplastic Large cell Ki 1 positive lymphomas, Primary Mediastinal B-Cell Lymphoma
        (PMBL), and B-Lymphoblastic lymphomas are ineligible.

        No previous chemotherapy. Patients who have received emergency irradiation and/or steroid
        therapy will be eligible ONLY if started on protocol therapy not more than 72 hours from
        the start of radiotherapy or steroids. Bone marrow and cerebrospinal fluid MUST be obtained
        before steroids are given for patient to be eligible for the study.

        Exclusion Criteria:

          -  Patients with newly diagnosed Group A (low risk) lymphoma. Patients with Group B
             (intermediate risk) if classified as Murphy Stage III/IV and diagnostic LDH &gt; 2 XULN
             and patients with primary mediastinal B-cell lymphoma (PMBL).

          -  Patients who have received any steroids in the week prior to diagnosis except as
             stated in Section 4.1.4 of the protocol.

          -  No congenital or acquired immune deficiency. These patients are excluded due to the
             expected intense immunosuppression, increased risk of opportunistic infections, and
             higher expected septic death rate in this subgroup of patients with this proposed
             therapy.

          -  No prior solid organ transplantation.

          -  Patients with previous malignancies that have been treated with systemic chemotherapy
             with alkylator or anthracycline therapy. The latter group of patients are excluded due
             to an expected increase in late effects (eg. late cardiac toxicity, secondary
             malignancies, sterility, etc.).

          -  Patients with known G6PD deficiency are NOT ELIGIBLE for Rasburicase therapy. Patients
             with G6PD deficiency should be treated with alkalinization, IV hydration and po and/or
             IV allopurinol during the reduction phase (COP).

        4.2.6 Patients with serious (sepsis, pneumonia, etc..) proven or suspected infections at
        diagnosis will be excluded.

        4.2.7 Pregnancy or Breast-Feeding: No information is available regarding human fetal or
        teratogenic toxicities. Pregnancy tests must be obtained in girls who are post-menarchal.
        Males or females of reproductive potential may not participate unless they have agreed to
        use an effective contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>31 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanton Goldman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical City Children's Hospital, Dallas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S Cairo, MD</last_name>
    <phone>914-594-2150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stanton Goldman, MD</last_name>
    <phone>972 566-6647</phone>
    <phone_ext>x4435</phone_ext>
    <email>stan.goldman@usoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Barth, MD</last_name>
      <email>Matthew.Barth@RoswellPark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell S Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Harrison, MSN</last_name>
      <email>lauren_harrison@nymc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Oesterheld, MD</last_name>
      <email>Javier.Oesterheld@carolinashealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimble Frazer, MD</last_name>
      <email>kimble-frazer@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pulsipher, MD</last_name>
      <email>michael.pulsipher@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Lymphoma (NOT primary mediastinal B-cell lymphoma)</keyword>
  <keyword>B-Cell---Burkitt's like</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Liposomal ARA-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

